Kathmandu
Cancer Center
Kathmandu
Cancer Center
Evidence-based tools for oncologists, pharmacists, and clinical teams. Built and maintained by KCC.
BSA using Mosteller formula with optional drug dose per m²
BSA = √[(Height × Weight) / 3600]Mosteller (1987) is the most widely used BSA formula in oncology trials. It correlates closely with DuBois for typical adult patients (BSA 1.5–2.2 m²).
BSA-based dosing standardises systemic exposure across body sizes. For narrow-therapeutic-index drugs (anthracyclines, taxanes, platinums) precision is critical. Use actual body weight unless institutional protocol specifies ideal or adjusted body weight for obese patients (BMI ≥ 30).
Calvert formula with Cockcroft-Gault GFR and evidence-based dose capping
Dose = AUC × (GFR + 25)Creatinine floor of 0.7 mg/dL prevents GFR overestimation in cachectic or sarcopaenic patients.
| AUC | Max dose |
|---|---|
| 7 | 1000 mg |
| 6 | 900 mg |
| 5 | 750 mg |
| 4 | 600 mg |
| 3 | 450 mg |
| 2 | 300 mg |
Contraindicated if GFR < 20 mL/min. Dose reduction at GFR 20–40 mL/min.
Predicts VTE risk in cancer patients initiating chemotherapy
Khorana et al. Blood 2008;111:4902–7| Factor | Pts |
|---|---|
| Stomach / Pancreas | 2 |
| Lung / Lymphoma / GYN / Bladder / Testicular | 1 |
| Plt ≥ 350 × 10⁹/L | 1 |
| Hgb < 10 g/dL or ESA use | 1 |
| WBC > 11 × 10⁹/L | 1 |
| BMI ≥ 35 kg/m² | 1 |
| Score | Risk | VTE rate (2.5 mo) |
|---|---|---|
| 0 | Low | ~0.3–0.8% |
| 1–2 | Intermediate | ~2% |
| ≥ 3 | High | ~6.7–7.1% |
Score ≥ 2 patients initiating systemic therapy should be offered primary thromboprophylaxis with a DOAC (apixaban 2.5 mg BD or rivaroxaban 10 mg OD) or LMWH, provided no significant bleeding risk. Reassess at each cycle as lab parameters change.
Biological Effective Dose and Equivalent Dose in 2 Gy fractions — for SBRT, brachytherapy, and fractionation comparison. Core tool for KCC's radiation oncology team. No other centre in Nepal has this online.
Coming SoonIdentifies low-risk febrile neutropenia patients eligible for outpatient oral antibiotic management. High-frequency daily use in medical oncology and haematology wards.
Coming SoonRadiobiological fractionation converter for SBRT, hypofractionation, and brachytherapy. Core tool for KCC's radiation oncology programme — no competitor in Nepal has this.
KCC PriorityRisk-stratifies febrile neutropenia to guide inpatient vs outpatient antibiotic management. High-frequency daily use on chemotherapy wards.
Coming SoonBidirectional PS converter with trial eligibility guidance. Useful for rapid documentation and referral letters.
Coming SoonGFR-gated cisplatin eligibility and hydration volume calculator. Natural companion to the carboplatin calculator for switching decisions.
Coming SoonEmetogenicity category lookup with ASCO/MASCC guideline antiemetic recommendations per regimen.
Coming Soon